The estimated Net Worth of Kleanthis G Xanthopoulos is at least $12.3 Tysiąc dollars as of 19 August 2016. Kleanthis Xanthopoulos owns over 15,920 units of Zosano Pharma Corp stock worth over $12,275 and over the last 12 years he sold ZSAN stock worth over $0. In addition, he makes $0 as Independent Director at Zosano Pharma Corp.
Kleanthis has made over 11 trades of the Zosano Pharma Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 15,920 units of ZSAN stock worth $21,014 on 19 August 2016.
The largest trade he's ever made was exercising 200,000 units of Zosano Pharma Corp stock on 17 April 2015 worth over $76,000. On average, Kleanthis trades about 16,658 units every 34 days since 2012. As of 19 August 2016 he still owns at least 21,920 units of Zosano Pharma Corp stock.
You can see the complete history of Kleanthis Xanthopoulos stock trades at the bottom of the page.
Dr. Kleanthis G. Xanthopoulos, Ph.D., is Independent Director of the Company. Dr. Xanthopoulos is the President and Chief Executive Officer and a member of the board of directors of Regulus Therapeutics Inc., having joined Regulus in 2007. Dr. Xanthopoulos is also currently chairman of the board of directors of Apricus Biosciences, Inc., a public company, a member of the board of directors of Biotechnology Industry Organization (BIO) and Senté Inc., and is a member of the executive board of BIOCOM, Southern California’s life science industry association. Prior to joining Regulus, Dr. Xanthopoulos was a managing director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals from its inception in 2000 to 2006, and remained a Director until its acquisition by Roche in 2011. Dr. Xanthopoulos was Vice President at Aurora Biosciences, which was acquired by Vertex Pharmaceuticals, from 1997 to 2000. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Previously, Dr. Xanthopoulos was an Associate Professor at the Karolinska Institute, in Stockholm, Sweden, after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden.
Kleanthis Xanthopoulos is 62, he's been the Independent Director of Zosano Pharma Corp since 2013. There are 1 older and 7 younger executives at Zosano Pharma Corp. The oldest executive at Zosano Pharma Corp is Dr. Donald J. Kellerman, 66, who is the VP of Clinical Devel. & Medical Affairs.
Kleanthis's mailing address filed with the SEC is C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT, CA, 94555.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L... oraz Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: